Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

HRTX


Fundamental

Company: Heron Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -0.12
Insider Own: 1.57%
Shs Outstand: 188.31M
Perf Week: 1.98%
Market Cap: 154.48M
Forward P/E: 6.30
EPS next Y: 0.13
Insider Trans: 0.00%
Shs Float: 185.57M
Perf Month: -17.08%
Enterprise Value: 249.54M
PEG: -
EPS next Q: -0.02
Inst Own: 82.45%
Short Float: 19.84%
Perf Quarter: -34.97%
Income: -20.20M
P/S: 1.00
EPS this Y: 83.33%
Inst Trans: -0.59%
Short Ratio: 20.57
Perf Half Y: -37.92%
Sales: 154.90M
P/B: 11.62
EPS next Y Percentage: 750.00%
ROA: -4.47%
Short Interest: 36.83M
Perf YTD: -36.97%
Book/sh: 0.07
P/C: 3.31
EPS next 5Y: -
ROE: -
52W High: 2.61 -68.61%
Perf Year: -56.41%
Cash/sh: 0.25
P/FCF: -
EPS past 3/5Y: 58.31% 45.44%
ROIC: -13.03%
52W Low: 0.74 11.30%
Perf 3Y: -64.06%
Dividend Est.: -
EV/EBITDA: 891.23
Sales past 3/5Y: 12.89% 11.81%
Gross Margin: 73.31%
Volatility W: 5.81%
Volatility M: 7.39%
Perf 5Y: -95.06%
Dividend TTM: -
EV/Sales: 1.61
EPS Y/Y TTM: -30.68%
Oper. Margin: -1.32%
ATR (14): 0.06
Perf 10Y: -96.02%
Dividend Ex-Date: -
Quick Ratio: 1.51
Sales Y/Y TTM: 7.36%
Profit Margin: -13.04%
RSI (14): 40.99
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 2.48
EPS Q/Q: -165.69%
SMA20: 0.06%
Beta: 1.41
Target Price: 4.33
Payout: -
Debt/Eq: 9.81
Sales Q/Q: -0.47%
SMA50: -21.01%
Rel Volume: 0.90
Prev Close: 0.83
Employees: 128
LT Debt/Eq: 9.81
Earnings: Feb 26 BMO
SMA200: -38.55%
Avg Volume: 1.79M
Price: 0.82
IPO: Aug 26, 1987
Option/Short: Yes / Yes
EPS/Sales Surpr.: 0.00% 1.81%
Trades:
Volume: 1,617,871
Change: -1.51%

Technical:


Latest News:

Heron Therapeutics (NASDAQ:HRTX) Earns Overweight Rating from Analysts at Capital ... somewhat bullish
HRTX

Summary: Capital One Financial initiated coverage on Heron Therapeutics with an overweight rating and a $6.00 price target. Other research analysts have also issued positive ratings for the company. Heron Therapeutics recently reported better-than-expected quarterly earnings. Institutional investors have shown interest in the company.

Full article
2024-04-24T18:45:09Z
Capital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight Recommendation very bullish
HRTX

Summary: Capital One initiated coverage of Heron Therapeutics (NasdaqCM:HRTX) with an Overweight recommendation and a projected 175.68% upside in the stock price. Multiple institutional investors hold significant amounts of shares in Heron Therapeutics.

Full article
2024-04-24T00:06:43Z